The Evolving Landscape Of Emerging Biopharma: Modern Trends And Flexible Trial Designs

By Jim Routt, Chief Operating Officer; Alexander Roland, Ph.D., R&D Research Director, The IQVIA Institute for Human Data Science; Gerard Brett, Head of Sales & Account Management, JAPAC

Emerging biopharma companies have become the engine of modern drug development, leading much of the early research and a growing share of clinical trials worldwide. But their success comes with strain. Tight budgets, cautious investors, a competitive talent market, and crowded therapeutic areas leave little room for missteps, while innovation hubs continue to spread across new regions.

In response, sponsors are rethinking how they run studies. Adaptive designs let teams adjust a trial mid-course rather than waste effort on a plan that no longer fits. Decentralized models, supported by virtual tools and local care sites, bring participation closer to patients and speed recruitment. Artificial intelligence is proving most useful when applied selectively to trial design, recruitment and forecasting, and gathering real-world evidence early helps meet the expectations of payers and regulators. If your team is trying to do more with limited resources, this brief helps you decide where flexibility, partnerships and technology can lower costs, shorten timelines and get promising therapies to patients sooner.